Corify Care, the medical technology company transforming the diagnosis and treatment of cardiac arrhythmias, has announced the close of a €3 million funding round advised by the firm RCD and led by Clave-Mondragón, alongside €3 million in public grants. This total financial backing of €6 million will enable Corify to roll out its ACORYS system across Europe and prepare for its entry into the U.S. market, with FDA Clearance expected in the coming months.
ACORYS: Real-time global cardiac mapping
ACORYS is an unprecedented system in the field of electrophysiology. Using 128 sensors strategically placed on the patient’s torso and advanced 3D reconstruction of the torso and heart, ACORYS provides real-time global mapping of cardiac electrical activity. This allows for the identification of arrhythmia circuits even before the introduction of the first catheter, revolutionizing the planning and execution of procedures in electrophysiology labs.
During interventions, ACORYS provides real-time, beat-by-beat assistance to the electrophysiologist, accelerating endocardial mapping and improving precision. This capability transforms invasive and prolonged procedures into faster, more efficient, and safer processes for patients.
Key clinical results
Recent studies have demonstrated ACORYS’s ability to identify patients in whom ablation for atrial fibrillation (AF) achieved 88.9% success rate, compared to 48.0% in patients requiring ablation outside the pulmonary veins. These results highlight ACORYS’s unique capacity to support more targeted and effective treatments, marking it as a disruptive advancement in clinical practice.
Corify Care will present the latest clinical results for ACORYS at the prestigious Heart Rhythm Society (HRS) congress, showcasing its role in procedures such as AF ablation and pacemaker implantation.
“The ability to electrically map the heart in real-time, with accuracy comparable to endocardial systems but at the speed of a standard ECG, is a game changer,” said Dr. Felipe Atienza, Chief Medical Officer of Corify Care.
A future of innovation: Beyond ACORYS
ACORYS is just the first version of a technology poised to continue achieving milestones in electrophysiology. Corify Care is developing a portfolio of solutions that integrate digital twins and artificial intelligence to take cardiac mapping to the next level. These technologies will enable even greater personalization in diagnosing and treating arrhythmias, solidifying Corify’s position as a global leader in cardiac innovation.
Growth and international expansion
The secured funding will allow Corify Care to consolidate its expansion in Europe and enter international markets, with activities planned in Germany and the United States by 2025. Additionally, the company has signed strategic agreements with Mondragón, ensuring scalability in device production to meet growing global demand.
“This year, we will almost triple the number of cases conducted in 2023, surpassing 1,500 treated patients. In 2025, we will launch activities in Germany and the United States, furthering our exponential growth,” said Andreu Climent, CEO of Corify Care.
Support from Clave-Mondragón
The funding round was led by Clave-Mondragón, whose manager, Alberto Bermejo, stated: “We are very excited to be part of this new stage for Corify Care. The company is demonstrating exceptional growth and significant clinical impact with ACORYS. We firmly believe this technology has the potential to lead a revolution in cardiac electrophysiology.”
Founded in 2019, Corify Care develops innovative solutions in cardiac electrophysiology. Its mission is to transform the diagnosis and treatment of heart diseases with fast, precise, and non-invasive tools. The company has received the support of the consultancy GENESIS Biomed since its inception, providing strategic and operational support and accompaniment in private and public fundraising activities, and currently belonging to the Board of Directors of Corify. Recognized as Europe’s most innovative company by the European Institute of Technology (EIT) in 2020, Corify continues to lead the technological revolution in cardiac health